Peroxisome proliferator-activated receptor-γ activation attenuates motor and cognition impairments induced by bile duct ligation in a rat model of hepatic cirrhosis

Pharmacology Biochemistry and Behavior

Volumn 120, Issue , 2014, Pages 133-139

  Aghaei, Iraj ^a   Shabani, Mohammad ^a   Doustar, Nikta ^c   Nazeri, Masoud ^b   Dehpour, Ahmadreza ^d  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bile duct ligation (BDL); Hepatic cirrhosis; Learning and memory; Motor function; Pioglitazone

Indexed keywords

BILIRUBIN; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; COGNITIVE DEFECT; CONTROLLED STUDY; LEARNING; LIVER CIRRHOSIS; MALE; MOTOR DYSFUNCTION; MUSCLE STRENGTH; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SPATIAL LEARNING; ANIMAL; AVOIDANCE BEHAVIOR; BILE DUCT; BILE DUCT DISEASE; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL LIVER CIRRHOSIS; LEARNING DISORDERS; LIGATION; MAZE TEST; MOTOR ACTIVITY; MOVEMENT DISORDERS; PSYCHOLOGY; WISTAR RAT;

ANIMALS; AVOIDANCE LEARNING; BILE DUCT DISEASES; BILE DUCTS; COGNITION DISORDERS; HYPOGLYCEMIC AGENTS; LEARNING DISORDERS; LIGATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MAZE LEARNING; MOTOR ACTIVITY; MOVEMENT DISORDERS; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84896928911     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.03.002     Document Type: Article

References (35)

1. Alkire MT, Nathan SV, McReynolds JR. Memory enhancing effect of low-dose sevoflurane does not occur in basolateral amygdala-lesioned rats. Anesthesiology 2005;103:1167-73. (Pubitemid 41692499)
2. Barbiero JK, Santiago RM, Lima M, Ariza D, Morais LH, Andreatini R, et al. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 2011;216:186-92.
3. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002;17:221-7. (Pubitemid 36204752)
4. Butterworth RF. Metal toxicity, liver disease and neurodegeneration. Neurotox Res 2010;18:100-5.
5. Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011;53:1372-6.
6. Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009;29:783-8.
7. Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci 2013;14:851-8.
8. Fruchart J, Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34.
9. Haghani M, Shabani M, Moazzami K. Maternal mobile phone exposure adversely affects the electrophysiological properties of Purkinje neurons in rat offspring. Neuroscience 2013;250:588-98.
10. Hajali V, Sheibani V, Esmaeili-Mahani S, Shabani M. Female rats are more susceptible to the deleterious effects of paradoxical sleep deprivation on cognitive performance. Behav Brain Res 2012;228:311-8.
11. Hosseini N, Nasehi M, Radahmadi M, Zarrindast M-R. Effects of CA1 glutamatergic systems upon memory impairments in cholestatic rats. Behav Brain Res 2013;256:636-45.
12. Huang L-T, Tiao M-M, Tain Y-L, Chen C-C, Hsieh C-S. Melatonin ameliorates bile duct ligation-induced systemic oxidative stress and spatial memory deficits in developing rats. Pediatr Res 2009;65:176-80.
13. Javadi-Paydar M, Ghiassy B, Ebadian S, Rahimi N, Norouzi A, Dehpour AR. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Behav Pharmacol 2013;24:195-206.
14. Jover R, Rodrigo R, Felipo V, Insausti R, Sáez?Valero J, García?Ayllón M, et al. Brain edema and inflammatory activation in bile duct ligated rats with diet?induced hyperammonemia: a model of hepatic encephalopathy in cirrhosis. Hepatology 2006;43:1257-66. (Pubitemid 43980104)
15. Kalonia H, Kumar P, Kumar A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-γ (PPARγ) in Huntington's disease. Pharmacol Biochem Behav 2010;96:115-24.
16. Kapadia R, Yi J-H, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813.
17. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994;43:204-11.
18. Kumar P, Kaundal RK, More S, Sharma SS. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009;197:398-403.
19. Lane JR, Starbuck EM, Fitts DA. Ethanol preference, metabolism, blood pressure, and conditioned taste aversion in experimental cholestasis. Pharmacol Biochem Behav 1997;57:755-66. (Pubitemid 27334423)
20. Leke R, Oliveira DL, Forgiarini LF, Escobar TD, Hammes TO, Meyer FS, et al. Impairment of short term memory in rats with hepatic encephalopathy due to bile duct ligation. Metab Brain Dis 2012:1-6.
21. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry E. Cannabidiol ameliorates cognitive and motor impairments in bile?duct ligated mice via 5?HT1A receptor activation. Br J Pharmacol 2010;159:950-7.
22. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51:528-34.
23. Napolitano M, Costa L, Palermo R, Giovenco A, Vacca A, Gulino A. Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res Bull 2011;85:231-7.
24. Nasehi M, Tackallou SH, Hasani I, Nasehi M. Cholestasis impaired spatial and non-spatial novelty detection in mice. J. Paramed. Sci. 2013;4:2008-4978.
25. Park S-W, Yi J-H, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007;320:1002-12. (Pubitemid 46294061)
26. Prakash A, Kumar A. Pioglitazone alleviates the mitochondrial apoptotic pathway and mito?oxidative damage in the d?galactose?induced mousemodel. Clin Exp Pharmacol P 2013;40:644-51.
27. Razavinasab M, Shamsizadeh A, Shabani M, Nazeri M, Allahtavakoli M, Asadi-Shekaari M, et al. Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease. Fundam Clin Pharmacol 2013;27:632-40.
28. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuatesmitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 2011;227:128-35.
29. Schuppan D, Afdhal N. Liver cirrhosis. Lancet 2008;371:838-51. (Pubitemid 351323895)
30. Shabani M, Hosseinmardi N, Haghani M, Shaibani V, Janahmadi M. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring. Neuroscience 2011;172:139-52.
31. Shabani M, Nazeri M, Parsania S, Razavinasab M, Zangiabadi N, Esmaeilpour K, et al. Walnut consumption protects rats against cisplatin-induced neurotoxicity. Neurotoxicology 2012;33:1314-21.
32. Sood V, Colleran K, Burge MR. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000;2:429-40.
33. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The PPAR-g agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011;8:91.
34. Xing B, Liu M, Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 2007;192:89-98.
35. Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J. The intracerebral application of the PPARα-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005;22:278-82. (Pubitemid 41059994)